Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
33 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to XBiotech Inc.’s names, not what it holds today.
Patents granted
33
33 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 2 in 2024 and 1 in 2023
Applications published
68
1 of them in 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
XBIOTECH INC. its own name
CA, as the owner printed on each patent
32 publishedXBiotech, Inc. its own name
named as the applicant on its applications, in CA
35 publishedXBiotech USA, Inc. a subsidiary
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Oct 15, 2024 | 12,116,405 | Arthritis treatment | Pharmaceuticals | XBIOTECH INC. |
| Mar 19, 2024 | 11,932,688 | Treatment for neoplastic diseases | Pharmaceuticals | XBIOTECH INC. |
| Oct 3, 2023 | 11,773,157 | Compositions and methods for treating and preventing Staphylococcus aureus infections | Pharmaceuticals | XBIOTECH INC. |
| Jun 28, 2022 | 11,370,831 | Compositions and methods for treating and preventing Staphylococcus aureus infections | Pharmaceuticals | XBIOTECH INC. |
| Mar 3, 2020 | 10,577,410 | Compositions and methods for treating and preventing Staphylococcus aureus infections | Pharmaceuticals | XBIOTECH INC. |
| May 21, 2019 | 10,294,296 | Treatment for neoplastic diseases | Pharmaceuticals | XBIOTECH INC. |
| Feb 26, 2019 | 10,214,581 | Compositions and methods for treating and preventing Staphylococcus aureus infections | Pharmaceuticals | XBIOTECH INC. |
| Feb 12, 2019 | 10,202,449 | Cachexia treatment | Pharmaceuticals | XBIOTECH INC. |
| Jun 5, 2018 | 9,988,447 | Treatment of diabetes | Pharmaceuticals | XBIOTECH INC. |
| Feb 27, 2018 | 9,902,769 | Treatment of dermatological pathologies | Pharmaceuticals | XBIOTECH INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Feb 13, 2025 | 2025/0051436 | Arthritis Treatment | Pharmaceuticals | XBiotech, Inc. |
| Jan 11, 2024 | 2024/0010711 | Compositions and methods for treating and preventing staphylococcus aureus infections | Pharmaceuticals | XBiotech, Inc. |
| Oct 12, 2023 | 2023/0322915 | True human antibody specific for interleukin 1 alpha | Biotechnology | XBiotech, Inc. |
| Sep 14, 2023 | 2023/0287104 | True human antibody specific for interleukin 1 alpha | Biotechnology | XBiotech, Inc. |
| Sep 14, 2023 | 2023/0287103 | True human antibody specific for interleukin 1 alpha | Biotechnology | XBiotech, Inc. |
| Sep 14, 2023 | 2023/0287102 | True human antibody specific for interleukin 1 alpha | Biotechnology | XBiotech, Inc. |
| Aug 11, 2022 | 2022/0251175 | Compositions and methods for treating and preventing staphylococcus aureus infections | Pharmaceuticals | XBiotech, Inc. · patent 11,773,157 granted from it |
| Feb 10, 2022 | 2022/0041710 | Treatment of brain ischemia-reperfusion injury | Pharmaceuticals | XBiotech USA, Inc. |
| Jan 21, 2021 | 2021/0017257 | Compositions and Methods for Treating and Preventing Staphylococcus Aureus Infections | Pharmaceuticals | XBiotech, Inc. |
| Apr 30, 2020 | 2020/0131252 | Compositions and methods for treating and preventing staphylococcus aureus infections | Pharmaceuticals | XBiotech, Inc. · patent 11,370,831 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.